公司股价表现 - Hologic股价大幅上涨7.6% [2] 并购动态 - 黑石集团与TPG重新启动对医疗设备制造商的收购谈判 [2] - 投资公司近期已与Hologic董事会重启磋商 [2]

CorMedix Inc. (NASDAQ:CRMD) is one of the best affordable biotech stocks to invest in now. On September 9, Citizens JMP analyst Jason Butler reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and set a price target of $22.00. Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? In other news, CorMedix Inc. (NASDAQ:CRMD) announced on September 2 the successful completion of its previously announced acquisition of Melinta Therapeutics LLC. Melinta Therapeutics LLC is a pri ...

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D ...

Neuroone Medical Technologies (NasdaqCM:NMTC) Conference September 17, 2025 12:15 PM ET Company ParticipantsRon Mcclurg - CFODave Rosa - President, CEO & DirectorNoneWith CEO Dave Rosa and CFO Ron McClurg of NeuroOne Medical Technologies Corporation, ticker NMTC. During the presentation, please feel welcome to submit questions using the Zoom Q&A interface at the bottom of your screen. After the presentation, we'll open to your questions. With that, Dave, I'll turn it over to you.Dave RosaAll right. Thanks, ...

投资策略 - 专注于收益型资产类别 提供可持续投资组合收入 分散化投资和通胀对冲机会 [1] - 关注具有防御性质股票 采用中长期投资视野 [2] 分析师背景 - 拥有超过14年投资经验 金融专业MBA学位 [2] - 通过股票所有权 期权或其他衍生品持有MDT多头仓位 [3] 服务模式 - 提供免费两周试用期 展示独家收益型投资组合中的顶级投资思路 [1] - 文章内容代表分析师个人观点 未获得除Seeking Alpha外任何补偿 [3]

公司业务与市场地位 - 公司是领先的持续葡萄糖监测（CGM）设备提供商 服务于数百万1型和2型糖尿病患者以及健康追踪人群 [2] - 公司成立于1999年 开创了准确实时的葡萄糖监测技术 改变了传统指尖采血的标准护理方式 [2] - 硬件仅占收入的5% 而一次性传感器占收入的95% 辅以行业领先的客户保留率 [3] 产品竞争优势 - 产品性能卓越且支持跨平台集成 包括G6、G7和Stelo等设备提供无缝连接 [2] - 竞争对手如雅培的FreeStyle Libre和美敦力的Guardian主要局限于自身生态系统 通常以价格而非创新竞争 [2] 财务表现与估值 - 截至9月12日 公司股价为76.22美元 [1] - 公司过去五年总回报率为负20% 表现不佳 [3] - 公司追踪市盈率为53.68倍 远期市盈率为29.41倍 [1] 增长机会 - 关键人群中的CGM渗透率仍然较低 包括美国超过1亿的2型糖尿病患者和前期糖尿病患者 [4] - 保险覆盖范围的扩大增强了采用潜力 [4] - 日本和沙特阿拉伯等国际市场渗透不足 提供额外增长空间 [4] - 通过Stelo进入非处方和健康市场可能创造新的收入流 [4] 风险与挑战 - 雅培低成本且广泛报销的FreeStyle Libre平台构成竞争挑战 [3] - 美敦力对下一代CGM的大量投资带来压力 [3] - GLP-1药物在糖尿病和肥胖领域的快速采用可能减少2型患者的需求 [3] - 自2025年5月以来 由于竞争和成本压力 股价已下跌约6% [5]

We came across a bullish thesis on Align Technology, Inc. on Flyover Stocks’s Substack by Todd Wenning. In this article, we will summarize the bulls’ thesis on ALGN. Align Technology, Inc.'s share was trading at $131.56 as of September 12th. ALGN’s trailing and forward P/E were 22.22 and 12.24 respectively according to Yahoo Finance. Kalcutta/Shutterstock.com Align Technologies (ALGN) is the company behind Invisalign, a clear plastic alternative to traditional metal braces, and is headquartered in Tempe ...

Watch the “What This Means” segment here MINNEAPOLIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it participated in a Virtual Investor “What This Means” segment. For the segment, Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has ...

Key Takeaways GEHC launched Voluson Performance 18 and 16 to advance maternal and reproductive care.GEHC's new AI-driven tools cut exam time by up to 75% and improve imaging precision.GEHC's Voluson systems earned FDA and CE approvals, supporting global rollout later this year.GE HealthCare (GEHC) recently unveiled the Voluson Performance 18 and 16, the latest generation of ultrasound systems in its women’s health portfolio. The launch underscores the company’s commitment to advancing maternal and reproduct ...

Key Points The company has a nearly 50-year history of annual dividend raises. Yet, the medical device maker is not usually flagged as a dividend stock. 10 stocks we like better than Medtronic › The list of Dividend Kings -- the very few U.S.-traded stocks that have enacted dividend raises at least once annually for a minimum of 50 years in a row -- is extremely short. That's why it's quite an event when a new stock joins this very limited and exclusive club. Barring a sudden collapse of its busin ...